{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-24-000074","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.262317+00:00","generated_at":"2026-06-03T05:11:01.712111+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Incyte Q1 revenues $881M (+9% YoY), GAAP EPS $0.75; to acquire Escient for $750M","bullets":["Revenue $881M (+9% YoY); GAAP net income $169.5M, diluted EPS $0.75.","Jakafi net revenues $572M (-1% YoY) despite 5% paid patient growth; inventory drawdown of ~$55M.","Opzelura revenues $86M (+52% YoY) driven by AD and vitiligo uptake.","Incyte to acquire Escient Pharmaceuticals for $750M plus net cash; lead candidate EP262 for CSU.","FY2024 guidance reaffirmed: Jakafi $2.69-2.75B; R&D $1.72-1.76B."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-24-000074","json":"https://secwatch.observer/filing/0000879169-24-000074.json","markdown":"https://secwatch.observer/filing/0000879169-24-000074.md","text":"https://secwatch.observer/filing/0000879169-24-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916924000074/0000879169-24-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916924000074/incy-20240430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:11:01.712111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c294566e1692b6c1f7bba43c389357a5d1a6be30","claim":"INCYTE CORP reported first fiscal quarter ended March 31, 2024 results: revenue Total revenues of $881 million in the first quarter (Q1'24). Guidance reaffirmed.","evidence_excerpt":"Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $881 million in the first quarter (Q1'24) (+9% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $572 million in Q1'24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of $2,690 - $2,750 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879169/000087916924000074/0000879169-24-000074-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first fiscal quarter ended March 31, 2024"},{"label":"Revenue","value":"Total revenues of $881 million in the first quarter (Q1'24)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}